Theravance Biopharma (FRA:0TB) PEG Ratio: N/A (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0TB Theravance Biopharma Inc FRA:0TB
72 GF Score
Price €14.60
GF Value €16.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Theravance Biopharma PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Theravance Biopharma's PE Ratio without NRI is 16.10. Theravance Biopharma's 5-Year EBITDA growth rate is 0.00%. Therefore, Theravance Biopharma's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Theravance Biopharma's PEG Ratio or its related term are showing as below:



FRA:0TB's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.945
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Theravance Biopharma  (FRA:0TB) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Theravance Biopharma PEG Ratio Related Terms


Theravance Biopharma PEG Ratio Historical Data

* Premium members only.

The historical data trend for Theravance Biopharma's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theravance Biopharma PEG Ratio Chart

Theravance Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Theravance Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:0TB vs ABUS, SANA, ANNX: PEG Ratio Comparison

For the Biotechnology subindustry, Theravance Biopharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's PEG Ratio falls into.


FRA:0TB
72GF Score
Theravance Biopharma Inc FRA:0TB
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theravance Biopharma PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Theravance Biopharma's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=16.097023153252/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18. GuruFocus considers Theravance Biopharma to be Modestly Undervalued.

Key valuation signals for FRA:0TB:

  • PEG Ratio: N/A
  • GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theravance Biopharma Business Description

Other Exchanges TBPH:USA
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score

Get the complete analysis for FRA:0TB

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price
€16.18
GF Value